摘要
目的:探讨降低原发性肝癌术后复发率的方法。方法:将70例原发性肝癌患者分为治疗组25例和对照组45例。治疗组于根治性手术后第4周行肝动脉栓塞化疗(TACE),并于术后第2周给予干扰素治疗1周,8周后重复化疗加干扰素治疗1次。对照组于根治性术后第4周行肝动脉栓塞化疗(TACE),8周后重复化疗1次。对每例患者进行2年随访,根据复发情况按时间分为6个月以内复发、6～12个月内复发、12～24个月内复发3组,并进行相关统计学分析。结果:治疗组25例,6个月内复发2例(8%),6～12个月内复发4例(16%),12～24个月内复发7例(28%);对照组45例6个月内复发4例(8.8%),6～12个月内复发8例(17.7%),12～24个月内复发21例(46.6%)。两组对比,6月内与6～12个月内复发患者治疗组较对照组减少,差异无统计学意义(P>0.05);12～24个月两组对比,治疗组复发率较对照组降低,差异具有统计学意义(P<0.05)。结论:干扰素联合早期区域化疗能迅速帮助患者恢复免疫功能,对降低肝癌的术后远期复发率有一定疗效。
Objective：To explore the method of decreasing the postoperative recurrence rate of hepatocellular carcinoma. Methods ： All of the 70 patients with hepatocellular carcinoma who underwent radical resection in our hospital were ran- domly di＇qided into two groups. The observed group （25 cases） were treated with TACE at the 4th weekend after radical resection, and interferon for 1 week at 2nd week,and repeat chemotherapy with interferon once after 8 weeks, while the control g＇oup（45 cases） were treated with TACE at the 4th weekend and repeat chemotherapy after 8 weeks. There was a follow-up study of 2 years for every patient of the two groups. According to the recrudesce time of cancer was divided into three groaps,less than 6 months,6 -12 months and 12 ~ 24 months. And results were statistically analyzed. Results：The number of 6 months,6 - 12 months and 12 - 24months recurrence cases was 2 （ 8 % ） ,4 （ 16 % ） and 7 （ 28 % ） in the ob- served group, and 4（8.8% ） ,8（ 17.7% ） ,21 （46.6%） in the control group. The number of 6 months,6 - 12 months re- currence cases in the observed group was less than the control group（P 〉 0.05, but the number of 12 -24months recur- rence cas.es with obvious difference between the two groups （ P 〈 0.05 ）. Conclusion： Interferon combined with TACE technique in the treatment will help the patients immunologic function recover to decrease hepatocellualr carcinoma post- operative recurrence rate.
出处
《赣南医学院学报》
2013年第2期206-208,共3页
JOURNAL OF GANNAN MEDICAL UNIVERSITY
基金
2008年赣州市科技局课题
关键词
干扰素
肝癌
原发性
区域性化疗
复发
Interferon
hepatocellular carcinoma
regional chemotherapy
recurrence
